CRL Stock Recent News

Get a deeper insight into the potential performance of Charles River (CRL) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

CRL's solid prospects in the DSA segment and strategic partnerships present a promising opportunity for investors.

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WILMINGTON, Mass. & DUBLIN--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River and Deciphex focus on advancing image management solutions, while developing novel AI tools for toxicologic pathology.

Growth across the Manufacturing and RMS segments is likely to have contributed to Charles River's fourth-quarter revenues.

CRL introduces Apollo for CRADL, integrating the technology stack across its robust portfolio.

WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River expands Apollo ecosystem, offering bespoke client experiences that enable data-driven decision making.

Atara has just announced a CRL by FDA for EBVALLO. EBVALLO is already approved in Europe since December 2022 and the cause of the CRL seems minor and easily addressable. The CRL has a major impact on cash runway, considering delay in milestone payments related to approval as well as future royalties. Nevertheless, ATRA remains eligible for these future payments. This forced ATRA to suspend its CAR-T pipeline in search for strategic alternatives. On the bright side, this creates another short-term catalyst and allows ATRA to focus resources on EBVALLO.

Charles River and Akron Bio collaborate to boost operations by integrating CGMP materials into the Cell Therapy Platform.

CRL's solid prospects in the RMS segment and solid financial stability create a favorable outlook for investors.